Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Alphcolin; Audes; CDP choline; CerAxon; Cytidil diphosphocholine; Hipercol; IP 302; Metanervon; Neurex; Neurox; Nicholin; Somazina; Startonyl; Trausan

Latest Information Update: 31 Jul 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Takeda
  • Developer Ferrer; Takeda
  • Class Neuroprotectants; Nootropics; Pyrimidine nucleotides; Small molecules; Trimethyl ammonium compounds
  • Mechanism of Action Hydroxy radical formation inhibitors; Phosphatidylcholine stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Brain injuries; Parkinson's disease; Stroke

Most Recent Events

  • 27 Jan 2006 IVAX Corporation has been acquired by Teva Pharmaceutical Industries
  • 27 Oct 2004 Citicoline has been licensed to IVAX Corporation in USA
  • 04 Jul 2002 Indevus has signed a non-binding memorandum of agreement with a privately held biotechnology company for further development of citicoline in the US and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top